To Demonstrate the Relative Bioavailability of Fluoxetine Hydrochloride Capsules, 40 mg

Sandoz

Status and phase: Completed; Phase 1

Conditions: Depression

Treatments: Drug: Fluoxetine Hydrochloride Capsules, 40 mg (Geneva Pharmaceutical, Inc); Drug: Fluoxetine Hydrochloride Capsules, 40 mg (Prozac) (Eli Lilly)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00947076

005-49-11634

Details and patient eligibility

About

To demonstrate the relative bioavailability of fluoxetine hydrochloride capsules, 40 mg.

Enrollment: 30 patients

Sex: All

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion criteria

• Positive test results for HIV or hepatitis B or C.
• Treatment for drug or alcohol dependence.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

30 participants in 2 patient groups

1

Experimental group

Description:

Fluoxetine Hydrochloride Capsules, 40 mg (Geneva Pharmaceutical, Inc)

Treatment:

Drug: Fluoxetine Hydrochloride Capsules, 40 mg (Geneva Pharmaceutical, Inc)

2

Active Comparator group

Description:

Fluoxetine Hydrochloride Capsules, 40 mg (Prozac) (Eli Lilly)

Treatment:

Drug: Fluoxetine Hydrochloride Capsules, 40 mg (Prozac) (Eli Lilly)